Link: https://links.sgx.com/1.0.0/corporate-announcements/00KHIE2ND190I0TX/3379331a60e45ae20d98836ae7ce4f202ce7de822e1d26565102d0cb99963aad

Summary:

• Tianjin Pharmaceutical Da Ren Tang Group, a key player in green Chinese traditional medicine, details its integrated value chain from R&D to manufacturing in its 2024 Annual Report.
• The report highlights an extensive product portfolio, featuring 599 medicine approvals and globally recognized traditional Chinese trademarks.
• The Group operates a robust nationwide marketing network and exports its traditional Chinese medicine products to over a dozen countries.
• Comprehensive financial statements, prepared in accordance with IFRS, are included in the report, providing a detailed view of the 2024 fiscal year performance.
• The report underscores a commitment to strong corporate governance, with the Audit Committee playing a key oversight role in financial and audit processes.